Who sold ccxi stock in the last quarter?
CCXI stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Wasatch Advisors Inc., Wells Fargo & Company MN, Susquehanna International Group LLP, Raymond James Financial Services Advisors Inc., Parallax Volatility Advisers L.P., BlackRock Inc., and Integral Health Asset Management LLC.
Is ChemoCentryx (ccxi) stock down 30% in a month?
ChemoCentryx shares are trading lower after the company reported worse-than-expected Q4 EPS and sales results. - Benzinga Down 30% In A Month, Is There More Pain For ChemoCentryx Stock? Sign up to receive the latest news and ratings for CCXI and its competitors with MarketBeat's FREE daily newsletter.
How can I get the latest news about ccxi?
Sign up to receive the latest news and ratings for CCXI and its competitors with MarketBeat's FREE daily newsletter. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Does ChemoCentryx stock have a dividend growth track record?
ChemoCentryx does not have a long track record of dividend growth. In the past three months, ChemoCentryx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,313,250.00 in company stock.
What is happening with ChemoCentryx?
ChemoCentryx (CCXI) Reports Q1 Loss, Misses Revenue Estimates. ChemoCentryx (CCXI) delivered earnings and revenue surprises of -83.33% and 78.77%, respectively, for the quarter ended March 2022.
Is CCXI a buy now?
ChemoCentryx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.
Will ChemoCentryx go up?
ChemoCentryx Inc (NASDAQ:CCXI) The 8 analysts offering 12-month price forecasts for ChemoCentryx Inc have a median target of 64.50, with a high estimate of 106.00 and a low estimate of 34.00. The median estimate represents a +175.52% increase from the last price of 23.41.
Did CCXI get approved?
Oct 8 (Reuters) - ChemoCentryx Inc (CCXI. O) said on Friday the U.S. health agency approved its lead drug for treating a rare, fatal autoimmune disease, sending the biopharmaceutical company's shares up by more than 70%.
Is ChemoCentryx a good stock?
What do analysts say about ChemoCentryx? ChemoCentryx's analyst rating consensus is a 'Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
Who makes Tavneos?
19, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that TAVNEOS® (avacopan) has been approved within the European Union in combination with a rituximab or cyclophosphamide regimen for the treatment of adult patients with severe, active granulomatosis polyangiitis (GPA) or microscopic ...
Will avacopan be approved by FDA?
FDA has approved Tavneos (avacopan) as an add-on treatment to standard therapy including glucocorticoids for adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis.
How many employees does ChemoCentryx have?
The company is also developing avacopan in other indications like complement 3 glomerulopathy and hidradenitis suppurativa, and plans to initiate a clinical study to evaluate the candidate in lupus nephritis patients.?...Compare CCXI With Other Stocks.ChemoCentryx Annual Number of Employees2019822018762017662016629 more rows
Should I buy or sell ChemoCentryx stock right now?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ChemoCentryx in the last year. There are currently 1 hold rating, 4 buy ra...
What is ChemoCentryx's stock price forecast for 2022?
6 Wall Street research analysts have issued 12-month price objectives for ChemoCentryx's stock. Their forecasts range from $38.00 to $110.00. On av...
How has ChemoCentryx's stock price performed in 2022?
ChemoCentryx's stock was trading at $36.41 at the start of the year. Since then, CCXI shares have decreased by 31.2% and is now trading at $25.05....
When is ChemoCentryx's next earnings date?
ChemoCentryx is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022. View our earnings forecast for ChemoCent...
How were ChemoCentryx's earnings last quarter?
ChemoCentryx, Inc. (NASDAQ:CCXI) issued its quarterly earnings results on Thursday, May, 5th. The biopharmaceutical company reported ($0.55) earnin...
Who are ChemoCentryx's key executives?
ChemoCentryx's management team includes the following people: Dr. Thomas J. Schall Ph.D. , Founder, Pres, CEO & Chairman (Age 63, Pay $1.21M) Ms...
What is Thomas J. Schall's approval rating as ChemoCentryx's CEO?
10 employees have rated ChemoCentryx CEO Thomas J. Schall on Glassdoor.com . Thomas J. Schall has an approval rating of 58% among ChemoCentryx's e...
Who are some of ChemoCentryx's key competitors?
Some companies that are related to ChemoCentryx include Amgen (AMGN) , Gilead Sciences (GILD) , Vertex Pharmaceuticals (VRTX) , Regeneron Pharm...
What other stocks do shareholders of ChemoCentryx own?
Based on aggregate information from My MarketBeat watchlists, some companies that other ChemoCentryx investors own include Exelixis (EXEL) , Ener...
Which institutional investors are selling ChemoCentryx stock?
Which institutional investors are buying ChemoCentryx stock?
CCXI stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Wasatch Advisors Inc., Wells Fargo & Company MN, Susquehanna International Group LLP, Raymond James Financial Services Advisors Inc., Parallax Volatility Advisers L.P., BlackRock Inc., and Integral Health Asset Management LLC.
How do I buy shares of ChemoCentryx?
CCXI stock was bought by a variety of institutional investors in the last quarter, including Pictet Asset Management SA, Millennium Management LLC, Marshall Wace LLP, Sofinnova Investments Inc., GW&K Investment Management LLC, Goldman Sachs Group Inc., Goldman Sachs Group Inc., and Principal Financial Group Inc.. View insider buying and selling activity for ChemoCentryx or or view top insider-buying stocks..
What is ChemoCentryx's stock price today?
Shares of CCXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
How much money does ChemoCentryx make?
One share of CCXI stock can currently be purchased for approximately $28.64.
Where are ChemoCentryx's headquarters?
ChemoCentryx has a market capitalization of $2.00 billion and generates $64.89 million in revenue each year. The biopharmaceutical company earns $-55.36 million in net income (profit) each year or ($1.74) on an earnings per share basis.
How can I contact ChemoCentryx?
ChemoCentryx is headquartered at 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043.
What happened
ChemoCentryx's mailing address is 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043. The biopharmaceutical company can be reached via phone at (650) 210-2900, via email at [email protected], or via fax at 650-210-2910.
So what
Shares of ChemoCentryx ( CCXI ) were crashing 46.5% lower as of 3:06 p.m. EDT on Tuesday. The huge decline came after the U.S. Food and Drug Administration (FDA) released briefing documents for an advisory committee scheduled to meet on Thursday to review the approval application for avacopan.
Now what
As you might have guessed from the collapse of the biotech stock today, the FDA's briefing documents didn't look very good for ChemoCentryx.
What is ChemoCentryx?
It's possible that the Arthritis Advisory Committee will still view ChemoCentryx's filing for avacopan in a positive light. That doesn't seem likely at this point, though, considering the strong language the FDA included in its briefing documents.
Where is ChemoCentryx located?
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States . It develops Avacopan, an orally administered selective complement 5a receptor inhibitor for the treatment of anti-neutrophil cytoplasmic ...
